Articles: cations.
-
As we begin a new year, the Editorial Board, Associate and Assistant Editors and Editor-in-Chief of mAbs would like to thank the reviewers who contributed their insights and advice, as well as suggestions for improvement of manuscripts submitted for publication in mAbs volume 5, issues 1-6 (2013). The peer-review process involved the investment of substantial time and effort by the experts listed below, and we sincerely appreciate their valuable input on the selection of relevant, high-quality articles for mAbs readers.
-
Sharing of raw research data is common in many areas of medical research, genomics being perhaps the most well-known example. In the clinical trial community investigators routinely refuse to share raw data from a randomized trial without giving a reason. ⋯ Technological developments, particularly the Internet, have made data sharing generally a trivial logistical problem. Data sharing should come to be seen as an inherent part of conducting a randomized trial, similar to the way in which we consider ethical review and publication of study results. Journals and funding bodies should insist that trialists make raw data available, for example, by publishing data on the Web. If the clinical trial community continues to fail with respect to data sharing, we will only strengthen the public perception that we do clinical trials to benefit ourselves, not our patients.
-
Editorial
Materializing research promises: opportunities, priorities and conflicts in translational medicine.
There is considerable evidence that the translation rate of major basic science promises to clinical applications has been inefficient and disappointing. The deficiencies of translational science have often been proposed as an explanation for this failure. An alternative explanation is that until recently basic science advances have made oversimplified assumptions that have not matched the true etiological complexity of most common diseases; while clinical science has suffered from poor research practices, overt biases and conflicts of interest. ⋯ Moreover, while the role of the industry is catalytic in translating research advances to licensed interventions, academic independence needs to be sustained and strengthened at a global level. Conflicts of interest may stifle translational research efforts internationally. The profit motive is unlikely to be sufficient alone to advance biomedical research towards genuine progress.